Global Vaginal Inserts demand is projected to be valued atUS$ 1.65 Billion in 2022, forecast to grow at a CAGR of 5.2% to be valued at US$ 2.7 Billion from 2022 to 2032. Growth is attributed to the rising demand for renovation projects and development in residential and commercial construction.
| Report Attribute | Details |
| Estimated Base Year Value (2021) | US$ 1.58 Billion |
| Expected Market Value (2022) | US$ 1.65 Billion |
| Anticipated Forecast Value (2032) | US$ 2.7 Billion |
| Projected Growth Rate (2022-2032) | 5.2% CAGR |
Vaginal Inserts are solid dosage drug form that is inserted into the vagina with the help of a special applicator. Vaginal inserts have advantages over other dosage forms as it will increase the local concentration of the drug and are also beneficial in refractory cases. Drugs taken in the form of vaginal inserts melt inside the body and absorb directly into the bloodstream.
Vaginal inserts can be used for several indications. Such as birth control, fungal infections, vaginal dryness, hormone supplementation, and vitamin supplementation.
The global vaginal Inserts market has witnessed growth due to the increasing use of vaginal inserts in birth control, fungal infections, vaginal dryness, hormone supplementation, and vitamin supplementation. With growing awareness about birth control, the use of contraceptive vaginal contraceptives is gaining popularity over conventional contraceptive pills due to its fewer side effects and also a major reason for the growth of the vaginal inserts market.
In the U.S. vaginal candidiasis is the second most common type vaginal infection next to bacterial vaginal infections. Clotrimazole vaginal inserts, Monistat 3 vaginal inserts, and Terconazole vaginal inserts are the first line of treatment for vaginal candidiasis. The incidence of vaginal candidiasis is rising globally. The rising incidence of vaginal candidiasis which required to use vaginal inserts for treatment is a vital factor that positively influences the growth of the market.
Moreover, the rising use of vaginal inserts for estrogen supplements, menstrual pain relief, and the treatment of vaginal dryness also fuelling the vaginal inserts market.
Although few factors such as mucosal irritation, patient compliance, and erratic and undesired absorption can restrain the concerned market.
Asia-Pacific accounted for the highest market share in 2020. The rise in the number of women populations in countries like India and China along with the rising inclination of females towards maintaining personal hygiene has driven the sales of feminine hygiene products ultimately contributing to the growth of the overall market. This awareness about vaginal hygiene has created a plethora of growth opportunities for vaginal inserts in the region.
Owing to the increased disposal of income and enhanced efforts by the government agencies towards increasing the awareness of intimate hygiene & the upward trend toward female hygiene products, the demand for vaginal inserts has increased in the European region.
As per the WHO’s report, the European Medicines Agency (EMA) has given approval to the dapivirine ring for HIV prevention for women in high HIV burden settings. An EMA positive opinion paves the way for regulatory approvals for the ring in countries where women could benefit from additional HIV prevention options.
North America’s Vaginal Inserts market is expanding because of the high adoption rate and it will remain dominant over the period of forecast due to the rising incidence of vaginal candidiasis and raising awareness for feminine hygiene.
As per market research, Feminine Hygiene products sales have increased tremendously in recent years, despite continued price pressure and fierce competition. Development in the organized retail market, technical advancements, and swelling demand for organic products has been the other factors driving the growth of the feminine hygiene products market.
Some of the key participants present in the global demand for Vaginal Inserts market include Meyer Organics Pvt Ltd, Rapross Pharmaceuticals Pvt Ltd, Endocare India, Skymax Laboratories Pvt Ltd, Indica Laboratories Pvt Ltd, Sanzyme Ltd, Hetero Drugs Ltd, Glenmark Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, and Aristo Pharmaceuticals Pvt Ltd.
| Report Attribute | Details |
| Growth Rate | CAGR of 5.2% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2016-2021 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
By Product Type:
By Applications:
By Distribution Channel:
By Region:
FMI projects the global demand of the vaginal inserts market to expand at a 5.2% value CAGR by 2032
North America is expected to be the most opportunistic vaginal inserts market
Meyer Organics Pvt Ltd, Rapross Pharmaceuticals Pvt. Ltd, Endocare India, Skymax Laboratories Pvt. Ltd and Indica Laboratories Pvt. Ltd are some prominent vaginal inserts manufacturers
Explore Similar Insights
Vaginal Inserts Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
